- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PP0663 | Recombinant Protein-Pasteurella haemolytica GS60 antigen (a.a.32 to 573) | Q51850 | 100 µg | 1195 | |
PP0664 | Recombinant Protein-Pasteurella haemolytica lipoprotein 1 PLP1 (a.a.20 – 277) | Q08868 | 100 µg | 1195 | |
PP0665 | Recombinant Protein-Pasteurella haemolytica lipoprotein 3 PLP3 (a.a.20 to 263) | Q08870 | 100 µg | 1195 | |
PP0666 | Recombinant Protein-Pasteurella haemolytica lipoprotein PlpE (a.a.31 to 338) | Q9ZHK7 | 100 µg | 1195 | |
PP0667 | Recombinant Protein-Pasteurella haemolytica P2 (a.a.24 to 364) | Q06PS5 | 100 µg | 1195 | |
PP0668 | Recombinant Protein-Pasteurella haemolytica Serotype-1-specific antigen (a.a.61 to 460) | Q51846 | 100 µg | 1195 | |
RPP0663 | cDNA-Pasteurella haemolytica GS60 antigen (a.a.32 to 573) | Q51850 | 2 µg | 2705 | |
RPP0664 | cDNA-Pasteurella haemolytica lipoprotein 1 PLP1 (a.a.20 – 277) | Q08868 | 2 µg | 1285 | |
RPP0665 | cDNA-Pasteurella haemolytica lipoprotein 3 PLP3 (a.a.20 to 263) | Q08870 | 2 µg | 1215 | |
RPP0666 | cDNA-Pasteurella haemolytica lipoprotein PlpE (a.a.31 to 338) | Q9ZHK7 | 2 µg | 1535 | |
RPP0667 | cDNA-Pasteurella haemolytica P2 (a.a.24 to 364) | Q06PS5 | 2 µg | 1700 | |
RPP0668 | cDNA-Pasteurella haemolytica Serotype-1-specific antigen (a.a.61 to 460) | Q51846 | 2 µg | 1995 |
Pasteurella haemolytica cDNA and recombinant antigen
Pasteurella haemolytica is a Gram-negative, non-spore-forming, facultatively anaerobic, rod-shaped bacterium found in various animals, including rabbits, rodents, cattle, sheep, cats, and dogs. It is a normal inhabitant of the upper respiratory tract, and it is also commonly found in the lower respiratory tract and in the oropharynx. P. haemolytica is a major cause of bovine pneumonic pasteurellosis, a respiratory disease characterized by fever, coughing, and production of mucopurulent exudate. It can also cause systemic diseases, including septicaemia, meningitis, and endocarditis. The primary mode of transmission is through inhalation of aerosols, direct contact with infected animals, ingestion of contaminated food, and contact with contaminated environment. One of its key features is the presence of different antigens and lipoproteins on its surface, which play a crucial role in its pathogenicity. In this article, we will discuss the various types of Pasteurella haemolytica antigens and lipoproteins, including the GS60 antigen, PLP1, PLP3, PlpE, P2, and Serotype-1-specific antigen, and their functions.
GS60 Antigen
The GS60 antigen is a major antigen found on the surface of Pasteurella haemolytica. It is a protein molecule that triggers an immune response when recognized by the host’s immune system. The GS60 antigen plays a significant role in the virulence of the bacteria by helping it evade the host’s immune system.
PLP1 and PLP3
PLP1 and PLP3 are lipoproteins that are involved in the adhesion of Pasteurella haemolytica to the host’s respiratory tract. These lipoproteins are critical for the bacteria to colonize and establish an infection in the host.
PlpE
PlpE is a surface-exposed lipoprotein that plays a vital role in the ability of Pasteurella haemolytica to resist the host’s immune response. This lipoprotein helps the bacteria evade the host’s immune system by inhibiting the complement pathway, a part of the immune system that helps to destroy foreign invaders.
P2
P2 is a surface protein that plays a crucial role in the adhesion and invasion of Pasteurella haemolytica into host cells. This protein binds to specific receptors on the host’s cells, allowing the bacteria to enter and cause infection.
Serotype-1-specific antigen
The serotype-1-specific antigen is a surface protein that is specific to serotype 1 of Pasteurella haemolytica. It is a key virulence factor in serotype 1 strains, playing a role in the bacteria’s ability to evade the host’s immune system.
Pasteurella haemolytica is a pathogenic bacterium that uses different antigens and lipoproteins to establish and maintain an infection in its host. Understanding the functions of these antigens and lipoproteins, such as the GS60 antigen, PLP1, PLP3, PlpE, P2, and Serotype-1-specific antigen, is crucial in developing effective strategies for preventing and treating infections caused by this bacteria. By targeting these antigens and lipoproteins, we can reduce the virulence of Pasteurella haemolytica and improve the outcomes of infected animals.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.
Pasteurella haemolytica cDNA and recombinant antigen can be used in a variety of applications, including medical diagnostics, vaccine development, and genetic engineering. In medical diagnostics, the cDNA and antigen can be used to detect the presence of the bacteria in a sample, as well as to differentiate between different species of Pasteurella. In vaccine development, the cDNA and antigen can be used to create a vaccine that can protect against the bacteria. Finally, in genetic engineering, the cDNA and antigen can be used to create transgenic animals or plants that are resistant to the bacteria.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple